Improving the managed introduction of new medicines: Sharing experiences to aid authorities across Europe

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 15, Issue 5, 2015, Pages 755-758

  Matusewicz, Wojciech ^a   Godman, Brian ^b,c,d   Pedersen, Hanne Bak ^e   Fürst, Jurij ^f   Gulbinovič, Jolanta ^g,h   Mack, Asbjørn ⁱ   Selke, Gisbert ^j   Timoney, Angela ^c,k   Warmińska, Ewa ^l   Malmström, Rickard E ^b  

^a Agency for Health Technology Assessment in Poland   (Poland)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

^e WHO REGIONAL OFFICE FOR EUROPE   (Denmark)

^f Health Insurance Institute   (Slovenia)

^g State Medicine Control Agency of Lithuania   (Lithuania)

^h VILNIUS UNIVERSITY   (Lithuania)

ⁱ Statistics Norway   (Norway)

^j Wissenschaftliches Institut der AOK WIdO   (Germany)

^k National Health Fund ^*  (United Kingdom)

^l National Health Fund   (Poland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; ANTIBIOTIC AGENT; BIOSIMILAR AGENT; DABIGATRAN; ENALAPRIL; IPILIMUMAB; LISINOPRIL; NEW DRUG; RAMIPRIL; RENIN INHIBITOR; DRUG;

BLEEDING; BUDGET; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG MARKETING; DRUG MONITORING; DRUG SCREENING; EUROPE; GERMANY; GROSS NATIONAL PRODUCT; HEALTH CARE QUALITY; HEALTH CARE UTILIZATION; HUMAN; INCREMENTAL COST EFFECTIVENESS RATIO; MEDICINE; MELANOMA; NATIONAL HEALTH INSURANCE; OUTCOME ASSESSMENT; PATIENT CARE; PHYSICIAN; PRACTICE GUIDELINE; PRESCRIPTION; QUALITY ADJUSTED LIFE YEAR; REIMBURSEMENT; SWEDEN; WORLD HEALTH ORGANIZATION; BIOMEDICAL TECHNOLOGY ASSESSMENT; DRUG APPROVAL; ECONOMICS; ORGANIZATION AND MANAGEMENT;

DRUG APPROVAL; EUROPE; HUMANS; PHARMACEUTICAL PREPARATIONS; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 84942838711     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/14737167.2015.1085803     Document Type: Conference Paper

References (22)

1. Godman B, Malmstrom RE, Diogene E, et al. Are new models needed to optimize the utilization of new medicines to sustain healthcare systems? Exp Rev Clin Pharmacol 2015;8(1):77-94
2. Godman B, Malmstrom RE, Diogene E, et al. Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs. Front Pharmacol 2014;5:109
3. Kaplan W, Wirtz V, Mantel-Teeuwisse A, et al. Priority medicines for europe and the world. 2013. Available from: www.who.int/medicines/areas/priority-medicines/MasterDocJune28-FINAL-Web.pdf?ua=1
4. WHO. Access to new medicines in Europe: technical review of policy initiatives and opportunities for collaboration and research. Available from: www.euro.who.int/en/health-topics/Health-systems/medicines/publications2/2015/access-to-new-medicines-in-europe-technical-review-of-policy-initiatives-and-opportunities-for-collaboration-and-research
5. Piperska group rational prescribing home page. Available from www.piperska.org/home
6. The agency for health technology assessment and tariff system (AOTMiT) Home Page. Available from: www.aotm.gov.pl/www/index.php?id=397
7. EFPIA. HEALTH & GROWTH - Evidence compendium. Available from: www.efpia.eu/uploads/Modules/Documents/health-and-growth-evidence-compendium.pdf [Last accessed 30 October 2013]
8. Gustafsson LL, Wettermark B, Godman B, et al. The 'wise list'- a comprehensive concept to select, communicate and achieve adherence to recommendations of essential drugs in ambulatory care in Stockholm. Basic clin Pharmacol Toxicol 2011;108(4):224-33
9. Bjorkhem-Bergman L, Andersen-Karlsson E, Laing R, et al. Interface management of pharmacotherapy. Joint hospital and primary care drug recommendations. Europ J Clin Pharmacol 2013;69(Suppl 1):73-8
10. Wettermark B, Persson ME, Wilking N, et al. Forecasting drug utilization and expenditure in a metropolitan health region. BMC health Ser Res 2010;10:128
11. Malmstrom RE, Godman BB, Diogene E, et al. Dabigatran - a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs. Front Pharmacol 2013;4:39
12. Joppi R, Pase D, Poggiani C. Italian horizon scanning project. G Ital Health Technol Assess 2013;6:11-21
13. Cochrane handbook for systematic reviews of interventions version 5.1.0. Available from: http://handbook.cochrane.org/
14. Scottish medicines consortium. guidance to manufacturers for completion of new product assessment form (NPAF). Available from: www.scottishmedicines.org.uk/Submission-Process/Submission-guidance-and-forms/Templates-Guidance-for-Submission/Templates-Guidance-for-Submission 2014
15. NHS lothian pharmacy strategy 2013-2016. Available from: www.nhslothian.scot.nhs.uk/OurOrganisation/Consultations/Current/Documents/PharmacyStrategy.pdf
16. Godman B, Paterson K, Malmstrom RE, et al. Improving the managed entry of new medicines: sharing experiences across Europe. Exp Rev Phar Out Res 2012;12(4):439-41
17. Wettermark B, Zoega H, Furu K, et al. The Nordic prescription databases as a resource for pharmacoepidemiological research-a literature review. Pharmacoepidemiol Drug Saf 2013;22(7):691-9
18. Campbell SM, Godman B, Diogene E, et al. Quality indicators as a tool in improving the introduction of new medicines. Basic Clin Pharmacol Toxicol 2015;116(2):146-57
19. Furst J, Cizman M, Mrak J, et al. The influence of a sustained multifaceted approach to improve antibiotic prescribing in Slovenia during the past decade: findings and implications. Exp Rev Anti Infect Ther 2015;13(2):279-89
20. 19th WHO. Model list of essential medicines. Available from: http://www.who.int/medicines/publications/essentialmedicines/EML2015-8-May-15.pdf?ua=1 2015
21. Kantarjian HM, Fojo T, Mathisen M, Zwelling LA. Cancer drugs in the United States: Justum Pretium - the just price. J Clin Oncol 2013;31(28):3600-4
22. Mack A. Norway, biosimilars in different funding systems. What works? Gen Bios Initiat (GABI) J 2015;4(2):90-2